A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
BUSINESS
MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
MSD K.K. is devoting its intensive resources and efforts to its anti-PD-1 antibody pembrolizumab, which is now under regulatory review in Japan, as it gears up for its launch and a string of planned indication expansions, the company’s executives said…
To read the full story
Related Article
- MSD Japan President Pins High Hopes on Keytruda Growth in 2017 after 7.8% Sales Dip
April 5, 2017
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- MSD Seeks Lung Cancer Indication for Pembrolizumab in Japan
March 1, 2016
- MSD Seeks Japan Approval for Pembrolizumab for Melanoma
December 24, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
BUSINESS
- Japan’s Big 4 Drug Wholesalers See Combined Profits Slip despite Sales Growth
November 13, 2026
- Pfizer Files Litfulo for Vitiligo in Japan
November 13, 2026
- Takeda Debuts Narcolepsy Drug Orzeyful in US after Japan, China
November 13, 2026
- Keytruda Holds Japan Sales Crown in July-September as Mounjaro Climbs: IQVIA
November 13, 2026
- Genmab Eyes Early Japan Launches for 2 Cancer Blockbuster Hopefuls
November 13, 2026
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…